Caladrius Biosciences (CLBS) Receives Media Sentiment Rating of 0.09
News stories about Caladrius Biosciences (NASDAQ:CLBS) have been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Caladrius Biosciences earned a news sentiment score of 0.09 on Accern’s scale. Accern also assigned media coverage about the biotechnology company an impact score of 46.0411035221788 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Shares of Caladrius Biosciences (NASDAQ:CLBS) traded down $0.02 during trading on Friday, reaching $3.43. The company had a trading volume of 33,900 shares, compared to its average volume of 59,617. Caladrius Biosciences has a twelve month low of $2.63 and a twelve month high of $7.79.
Caladrius Biosciences (NASDAQ:CLBS) last issued its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.38) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.41. Caladrius Biosciences had a negative return on equity of 96.80% and a negative net margin of 84.10%. analysts expect that Caladrius Biosciences will post -2.33 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION WARNING: “Caladrius Biosciences (CLBS) Receives Media Sentiment Rating of 0.09” was posted by Watch List News and is the property of of Watch List News. If you are reading this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be read at https://www.watchlistnews.com/caladrius-biosciences-clbs-receives-media-sentiment-rating-of-0-09/1766250.html.
About Caladrius Biosciences
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.